Rita Nanda
丽塔·南达
MD
Associate Professor of Medicine; Director, Breast Oncology Program医学副教授；乳腺肿瘤学项目主任
👥Biography 个人简介
Rita Nanda, MD is Director of the Breast Oncology Program at the University of Chicago Medicine, with expertise in triple-negative and hereditary breast cancer. She led pivotal early immunotherapy trials in TNBC and has contributed substantially to defining the role of pembrolizumab and PARP inhibitors in BRCA-mutated breast cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Pembrolizumab in TNBC
Conducted one of the first pembrolizumab trials in metastatic TNBC, demonstrating durable responses in PD-L1–positive patients and establishing proof-of-concept for checkpoint blockade in breast cancer.
PARP Inhibition in Hereditary Breast Cancer
Led clinical and translational studies of olaparib and other PARP inhibitors in BRCA1/2-mutated breast cancer, helping define optimal combinations and addressing acquired resistance mechanisms.
Representative Works 代表性著作
Pembrolizumab in Patients with Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Journal of Clinical Oncology (2016)
First published pembrolizumab data in metastatic TNBC showing 18.5% overall response rate in PD-L1+ patients, foundational for subsequent KEYNOTE-522 and KEYNOTE-355 trials.
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (OlympiAD)
New England Journal of Medicine (2017)
Landmark trial establishing olaparib superiority over standard chemotherapy in BRCA-mutated HER2-negative metastatic breast cancer, leading to FDA approval.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 丽塔·南达 的研究动态
Follow Rita Nanda's research updates
留下邮箱，当我们发布与 Rita Nanda（University of Chicago Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment